1Giles RV, Ruddell CJ,Spiller DG.Single base discrimination for ribonuclease H-dependent antisense effects within intacthuman leukemia cells. [J].Nucleic Acids Res,1995,23:954-961.
2M Ian,Phillips SM,Galli. The potential role of antisense oligodeoxynucleotidetherapy for cardiovascular disease[J].Drugs,2000 Aug,60(2):239-248.
3Georg Sczakiel. Theoretical and experimental approaches to design effectiveantisense oligonucleotides[J].Frontiers in Bioscience,2000,1(5):d194-201.
4Allen TM. Liposomes:opportunities in drug delivery[J].Drugs,1997,54(suppl 4):8-14.
5Liu Y, Mounkes LC, Liggitt HD, et al. Factors influencing the efficiency ofcationic liposome-mediated intravenous gene delivery[J].Nat Biotechnic,1997,15:167-173.
6Donna Wielbo, Conrad Sernia, Robert Gyurko. Antisense inhibition of hypertension inthe spontaneously hypertensive rats[J].Hypertens,1995,25:314-319.
7Elena P, Umberto G, Liberato B, et al. In vivo effects of partial phosphorothioatedAT1 receptor antisense oligonucleotides in spontaneously hypertensive and normotensiverats[J].Life Sci,2000,(66):2091-2099.
8Gyurko R, Tran D, Phillips MI. Time course of inhibition of hypertension byanrtisense oligonucleotides targeted to AT1 angiotensin receptor mRNA in spontaneouslyhypertensive rats. Am J of Hypertens,1997,(10):56s-62s.
9Shuntaro Kagiyama, Adrian VM,Ian Phillips. Antisense inhibition of brainrenin-angiotensin system decreased blood pressure in chronic 2-kidney,1 clip hypertensiverats[J].Hypertens,2001,37(part2):371-375.
10Pen JF, Kimura B, Fregly M, et al. Reduction of cold-induced hypertension byantisense oligodeoxynucleotides to angiotensingen mRNA and AT1 receptor mRNA in brain andblood[J].Hypertens,1998,31:1317-23.
3Ferrari P, Ferrandi M, Tripodi L, et al. PST2238: a new antihypertensive compound that modulates Na^+, K^+ - ATPase in genetic hypertension[J] .J Pharm Exp Ther, 1999, 288:1074-1083.
4Ian M, Phillips SM, Galli. The potential role of antisense oligodeoxynucleotide therapy for cardiovascular disease[ J ]. Drugs, 2000, 60 (2) : 239-248.
5Kendall M J, Toeseu V. The HOT Study. Hypertension Optimal Therapy[J], J Clin Pharm Ther, 1998, 23(2) : 137-139,.
6Stamler J, Stamler R, Neaton JD, et al. Blood pressure, systolic and diastolic, and cardiovascular risks, CLS population data [J]. Arch InternMed, 1993,153(5) :598-615.
7Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat ana'iotensinozen[ J]. Hvvertension, 1995,26( 1 ) : 131-136.
8Gyurko R,Wielbo D, Phillips MI. Antisense inhibition of AT, receptor mRNA and anglotensin mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenie origin[J].Regul Pept,1993,49(2):167-174.
9Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension anew strategy for renin-angiotensin candidate genes [J]. Kidney Int,1994,46(6) : 1554-1556.
10Ambuhl P, Gyurko R, Phillips MI. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the anglotensin AT1 receptor[J]. Regul Pept, 1995,59(2) : 171-182.
